Research

Hormonal

Once-weekly long-acting release (LAR) exenatide (2.0 mg) significantly reduces HbA1c and body weight in patients with type 2 diabetes compared to placebo.

If you have type 2 diabetes and struggle with blood sugar and weight, a once-weekly injection of exenatide (2.0 mg) can significantly lower your A1c and help you lose weight. It works by mimicking a natural hormone that regulates blood sugar. While nausea is a common side effect, it is usually mild and improves over time. This treatment is designed for people who are already taking metformin or managing their diet and exercise but need additional help.

ModerateSupportsMEDIUM confidence
Exenatide LAR reduced mean (± SE) A1C by −1.4 ± 0.3% (0.8 mg) and −1.7 ± 0.3% (2.0 mg), compared with −0.4 ± 0.3% with placebo LAR (P < 0.0001 for both)... Subjects receiving 2.0 mg exenatide LAR had body weight reductions (−3.8 ± 1.4 kg) (P < 0.05)
Dennis Kim et al. · Diabetes Care · 2007

Why this rating

Phase 2 randomized, placebo-controlled trial, but with a small sample size (n=45) and short duration (15 weeks).

Source

Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes

Dennis Kim et al. · Diabetes Care · 2007

DOI 10.2337/dc06-2375

rct · n=45Cited 446×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →